Hospital
West Florida Regional Medical Center, INC.
West Florida Regional Medical Center, INC. was paid $17.64M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 99283, emergency room visit (moderate) — 36% of everything it billed.
33Billing provider infoWEST FLORIDA REGIONAL MEDICAL CENTER, INC.
PENSACOLA, FL 32514
PENSACOLA, FL 32514
33aNPI1639116726assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.64M
24GClaims768,956
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#23 of 163
Median peer was paid$4.77M
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,777 | $632K | |
| 2019 | 150,636 | $1.76M | |
| 2020 | 133,349 | $1.74M | |
| 2021 | 151,791 | $3.27M | |
| 2022 | 150,576 | $4.62M | |
| 2023 | 85,661 | $3.40M | |
| 2024incomplete | 44,166 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 80,884 | 72,106 | $6.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 40,580 | 34,174 | $2.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.0% | 14,860 | 13,719 | $1.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 5,425 | 4,737 | $754K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.6% | 1,886 | 1,736 | $628K |
| J7030 | Infusion, normal saline solution , 1000 cc | 3.1% | 15,095 | 12,326 | $554K |
| 80053 | Comprehensive metabolic panel | 3.0% | 39,101 | 31,297 | $522K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 6,503 | 5,199 | $434K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 3,437 | 3,204 | $339K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 5,562 | 4,657 | $312K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.6% | 502 | 457 | $278K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 7,391 | 6,001 | $273K |
201 more codes
| 87430 | 1.4% | 9,357 | $239K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,912 | $194K |
| 84703 | 1.1% | 20,495 | $188K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 12,049 | $181K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.0% | 1,320 | $177K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,569 | $130K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,975 | $110K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,093 | $104K |
| G0378 | Hospital observation service, per hour | <1% | 7,349 | $97K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,749 | $91K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 593 | $91K |
| C1729 | Catheter, drainage | <1% | 4,892 | $87K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,676 | $87K |
| A9270 | Non-covered item or service | <1% | 17,514 | $77K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,163 | $73K |
| 42830 | <1% | 224 | $60K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,756 | $54K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,195 | $48K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,735 | $48K |
| 73630 | <1% | 2,291 | $47K | |
| 73610 | <1% | 1,835 | $44K | |
| 87420 | <1% | 1,049 | $44K | |
| 85027 | <1% | 52,761 | $42K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,760 | $36K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,249 | $36K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,409 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,015 | $35K |
| 73130 | <1% | 1,489 | $34K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,335 | $34K |
| 73564 | <1% | 2,018 | $33K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,309 | $33K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,386 | $32K |
| 73110 | <1% | 1,092 | $30K | |
| 10060 | <1% | 549 | $28K | |
| 81003 | <1% | 24,818 | $27K | |
| 12001 | <1% | 405 | $27K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,169 | $25K |
| 72100 | <1% | 1,733 | $25K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,635 | $25K |
| 81001 | <1% | 12,600 | $24K | |
| 84702 | <1% | 2,358 | $23K | |
| 73030 | <1% | 1,556 | $22K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,027 | $21K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,664 | $21K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 111 | $19K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,726 | $18K |
| 87040 | <1% | 5,860 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,776 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,007 | $14K |
| 84484 | <1% | 13,731 | $13K | |
| 74018 | <1% | 838 | $13K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 633 | $13K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,692 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,447 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,303 | $12K |
| 70486 | <1% | 266 | $11K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 997 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,001 | $10K |
| 87077 | <1% | 870 | $10K | |
| 85610 | <1% | 4,619 | $10K | |
| 97116 | <1% | 365 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,738 | $9K |
| 73140 | <1% | 290 | $9K | |
| 93971 | <1% | 1,128 | $9K | |
| 97163 | <1% | 199 | $9K | |
| 88304 | <1% | 1,133 | $9K | |
| 85730 | <1% | 4,082 | $9K | |
| 83690 | <1% | 16,465 | $9K | |
| 83735 | <1% | 14,460 | $8K | |
| 12011 | <1% | 105 | $8K | |
| 76801 | <1% | 1,263 | $8K | |
| 87070 | <1% | 2,616 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 599 | $7K |
| 73502 | <1% | 815 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,044 | $7K |
| 93017 | <1% | 600 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 801 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,621 | $7K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 438 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 715 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 302 | $6K |
| 72072 | <1% | 154 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,222 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 707 | $5K |
| 73080 | <1% | 304 | $5K | |
| 00731 | <1% | 257 | $5K | |
| 86850 | <1% | 1,616 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,511 | $4K |
| 83880 | <1% | 3,309 | $4K | |
| 87210 | <1% | 1,862 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,474 | $4K |
| 71250 | <1% | 191 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 91 | $4K |
| 74022 | <1% | 360 | $4K | |
| 00126 | <1% | 875 | $4K | |
| 80076 | <1% | 2,757 | $4K | |
| 82550 | <1% | 2,946 | $4K | |
| 88342 | <1% | 163 | $4K | |
| 83605 | <1% | 5,774 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,300 | $3K |
| 73090 | <1% | 169 | $3K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 1,158 | $3K |
| C1769 | Guide wire | <1% | 696 | $3K |
| 80047 | <1% | 701 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,681 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,890 | $3K |
| 82553 | <1% | 1,392 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,433 | $3K |
| 85378 | <1% | 2,193 | $2K | |
| 73590 | <1% | 143 | $2K | |
| 86900 | <1% | 2,168 | $2K | |
| 87186 | <1% | 2,379 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,777 | $2K |
| 78451 | <1% | 30 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 286 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,777 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,170 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,004 | $1K |
| 86901 | <1% | 2,168 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,103 | $1K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 425 | $1K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 72 | $1K |
| 72050 | <1% | 28 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,410 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,751 | $1K |
| 80061 | Lipid panel | <1% | 1,473 | $1K |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 580 | $1K |
| 72131 | <1% | 21 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,075 | $990.20 |
| 71101 | <1% | 76 | $966.13 | |
| 12002 | <1% | 15 | $949.93 | |
| 82248 | <1% | 778 | $911.05 | |
| 87088 | <1% | 2,278 | $891.73 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 318 | $880.11 |
| 87205 | <1% | 326 | $862.80 | |
| 29125 | <1% | 68 | $824.39 | |
| 93970 | <1% | 93 | $812.65 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 150 | $748.47 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 205 | $707.26 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 917 | $704.76 |
| 90714 | <1% | 416 | $694.55 | |
| 84439 | <1% | 690 | $684.63 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,224 | $623.88 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 519 | $616.10 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 38 | $605.58 |
| 84100 | <1% | 1,677 | $580.44 | |
| 85007 | <1% | 481 | $579.29 | |
| 96376 | <1% | 789 | $536.22 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $472.85 |
| 86141 | <1% | 1,567 | $432.53 | |
| 72040 | <1% | 26 | $399.80 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 32 | $356.85 |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 15 | $332.88 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,670 | $331.19 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 118 | $319.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,333 | $317.16 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 170 | $304.73 |
| 82009 | <1% | 318 | $273.46 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 158 | $270.00 |
| 85651 | <1% | 1,606 | $262.86 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,038 | $248.71 |
| 87400 | <1% | 259 | $247.25 | |
| 80329 | <1% | 445 | $214.21 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,380 | $191.46 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 35 | $141.07 |
| 76775 | <1% | 43 | $118.01 | |
| 82607 | <1% | 321 | $110.15 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 776 | $103.62 |
| 90715 | <1% | 167 | $85.03 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 60 | $69.66 |
| 84156 | <1% | 68 | $65.83 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 77 | $48.85 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 220 | $48.85 |
| 93976 | <1% | 17 | $43.91 | |
| 82077 | <1% | 668 | $41.66 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 431 | $40.94 |
| 82570 | <1% | 47 | $39.34 | |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 29 | $38.23 |
| 86140 | <1% | 283 | $26.74 | |
| 86592 | <1% | 15 | $6.55 | |
| 82150 | <1% | 146 | $4.94 | |
| 84132 | <1% | 39 | $2.94 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 325 | $0.66 |
| 80320 | 0% | 208 | $0.00 | |
| 86308 | 0% | 26 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 22 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 44 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 44 | $0.00 |
| 97162 | 0% | 13 | $0.00 | |
| 74019 | 0% | 18 | $0.00 | |
| 83615 | 0% | 20 | $0.00 | |
| S5000 | Prescription drug, generic | 0% | 241 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 65 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,040 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 116 | $0.00 |
| 00840 | 0% | 58 | $0.00 | |
| 87634 | 0% | 906 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 59 | $0.00 |
| 85014 | 0% | 16 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 38 | $0.00 |
| 84550 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSUITT, RACHEL (CFO)